Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation

• Published in: Scientific reports Vol. 11; no. 1; p. 20689
• Main Authors: Gozzo, L., Di Lenarda, A., Mammarella, F., Olimpieri, P. P., Cirilli, A., Cuomo, M., Gulizia, M. M., Colivicchi, F., Murri, G., Kunutsor, S. K., Gabrielli, D., Trotta, F.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.10.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 692/699/75/29/1309; 692/700/565/1436; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Anticoagulants - administration & dosage; Atrial Fibrillation - drug therapy; Bleeding; Cardiac arrhythmia; Cohort Studies; Drug dosages; Female; Fibrillation; Hemorrhage - chemically induced; Humanities and Social Sciences; Humans; Italy; Kidney diseases; Male; multidisciplinary; Patients; Regression analysis; Science; Science (multidisciplinary); Vitamin K; Vitamin K - antagonists & inhibitors; Italy
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-99818-4

This study aims to provide real-world data about starting-dose of NOACs and dose-adjustment in patients with atrial fibrillation (AF). In fact, even if new oral anticoagulation agents (NOACs) have a predictable effect without need for regular monitoring, dose-adjustments should be performed according to the summary of product information and international guidelines. We employed the Italian Medicines Agency monitoring registries comprising data on a nationwide cohort of patients with AF treated with NOACs from 2013 to 2018. Logistic regression analysis was used to evaluate the determinants of dosage choice. During the reference period, treatment was commenced for 866,539 patients. Forty-five percent of the first prescriptions were dispensed at a reduced dose (dabigatran 60.3%, edoxaban 45.2%, apixaban 40.9%, rivaroxaban 37.4%). The prescription of reduced dose was associated with older age, renal disease, bleeding risk and the concomitant use of drugs predisposing to bleeding, but not with CHA 2 DS 2 -VASc and HAS-BLED. A relative reduction of the proportion of patients treated with low dosages was evident overtime for dabigatran and rivaroxaban; whereas prescription of low dose apixaban and edoxaban increased progressively among elderly patients. Evidence based on real-world data shows a high frequency of low dose prescriptions of NOACs in AF patients. Except for older age, renal disease, bleeding risk and the concomitant use of drugs predisposing to bleeding, other factors that may determine the choice of reduced dose could not be ascertained. There may be potential under-treatment of AF patients, but further evaluation is warranted.